CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma

Journal of Clinical Pathology

Volumn 64, Issue 3, 2011, Pages 246-251

  Ling, Yang ^a   Huang, Guoliang ^b   Fan, Lieying ^c   Wei, Lixin ^d   Zhu, Jing ^a   Liu, Yongping ^a   Zhu, Changtai ^a   Zhang, Changsong ^c  

^a SOOCHOW UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P14; PROTEIN P15; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P57; PROTEIN P73; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER SURVIVAL; CELL CYCLE REGULATION; CONTROLLED STUDY; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DNA METHYLATION; DYSPLASIA; EPIGENETICS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; METASTASIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; PROGNOSIS;

EID: 79951958851     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.082875     Document Type: Article

References (40)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009;24:729-35.
3. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
4. Lin DC, Du XL, Wang MR. Protein alterations in ESCC and clinical implications: a review. Dis Esophagus 2009;22:9-20.
5. Kuwano H, Kato H, Miyazaki T, et al. Genetic alterations in esophageal cancer. Surg Today 2005;35:7-18. (Pubitemid 40941123)
6. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002;2:103-12. (Pubitemid 41039110)
7. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001;58:1907-22.
8. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95. (Pubitemid 32204552)
9. Xiong Y, Zhang H, Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993;7:1572-83. (Pubitemid 23234350)
10. Reynisdottir I, Massague J. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997;11:492-503. (Pubitemid 27097647)
11. Prabhu NS, Somasundaram K, Satyamoorthy K, et al. p73beta, unlike p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing cancer cells. Int J Oncol 1998;13:5-9.
12. Watanabe H, Pan ZQ, Schreiber-Agus N, et al. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci U S A 1998;95:1392-7.
13. Shin JY, Kim HS, Park J, et al. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res 2000;60:262-5. (Pubitemid 30070747)
14. Brugarolas J, Chandrasekaran C, Gordon JI, et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552-7.
15. Rigberg DA, Kim FS, Blinman TA, et al. p21 expression is increased by irradiation in esophageal squamous cell carcinoma. J Surg Res 1998;76:137-42. (Pubitemid 28360011)
16. Nita ME, Nagawa H, Tominaga O, et al. p21Waf1/Cip1 expression is a prognostic marker in curatively resected esophageal squamous cell carcinoma, but not p27Kip1, p53, or Rb. Ann Surg Oncol 1999;6:481-8. (Pubitemid 29379567)
17. Natsugoe S, Nakashima S, Matsumoto M, et al. Expression of p21WAF1/Cip1 in the p53-dependent pathway is related to prognosis in patients with advanced esophageal carcinoma. Clin Cancer Res 1999;5:2445-9. (Pubitemid 29437326)
18. Delcuve GP, Rastegar M, Davie JR. Epigenetic control. J Cell Physiol 2009;219:243-50.
19. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010;31:27-36.
20. Smeds J, Berggren P, Ma X, et al. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14 (ARF)) and p53 genes are major targets for inactivation. Carcinogenesis 2002;23:645-55. (Pubitemid 34498503)
21. Xing EP, Nie Y, Song Y, et al. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999;5:2704-13. (Pubitemid 29493943)
22. Nie Y, Liao J, Zhao X, et al. Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis 2002;23:1713-20. (Pubitemid 35214957)
23. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999;96:8681-6. (Pubitemid 29354851)
24. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-93.
25. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010;17:1721-4.
26. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6. (Pubitemid 26296693)
27. Yin D, Xie D, Hofmann WK, et al. Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors. Oncogene 2002;21:8372-8. (Pubitemid 35477879)
28. Brakensiek K, Langer F, Kreipe H, et al. Absence of p21(CIP 1), p27(KIP 1) and p 57 (KIP 2) methylation in MDS and AML. Leuk Res 2005;29:1357-60.
29. Nakamura M, Sakaki T, Hashimoto H, et al. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas. Cancer Res 2001;61:6335-9. (Pubitemid 32783233)
30. Amatya VJ, Naumann U, Weller M, et al. TP53 promoter methylation in human gliomas. Acta Neuropathol 2005;110:178-84. (Pubitemid 41245207)
31. Chim CS, Fung TK, Wong KF, et al. Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients. J Clin Pathol 2006;59:921-6. (Pubitemid 44422844)
32. Yu J, Zhang H, Gu J, et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 2004;4:65.
33. Simpson DJ, Hibberts NA, McNicol AM, et al. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 2000;60:1211-16. (Pubitemid 30151985)
34. Toyota M, Ahuja N, Suzuki H, et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999;59:5438-42. (Pubitemid 29526452)
35. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-93. (Pubitemid 43980599)
36. Issa JP, Shen L, Toyota M. CIMP, at last. Gastroenterology 2005;129:1121-4. (Pubitemid 41242702)
37. Ishii T, Murakami J, Notohara K, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut 2007;56:13-19. (Pubitemid 46044883)
38. Teodoridis JM, Hardie C, Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 2008;268:177-86.
39. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000;60:5021-6.
40. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-18. (Pubitemid 32695034)